CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PREDICT aims to provide personalized treatment strategies for lung cancer patients with KRAS mutations. By utilizing genetic tools and in vitro testing, the project seeks to identify effective therapies based on individual genetic profiles, improving treatment outcomes.
Problem:In 2022, more than half a million lung cancer patients worldwide carrying KRAS mutations faced therapy resistance, a trend on the rise.
Such cancers resist standard treatments and targeted therapies, leading to an average survival of 1.2 years post-treatment.
The heterogeneous genetic background of KRAS-driven cancer adds further complexity, hindering personalized treatment due to resistance unpredictability.Solution:Our Proof Of Concept (PoC) project PREDICT provides a personalized trea…
UNIVERSITA DEGLI STUDI DI TORINO
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, ROMA RM
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
